Welcome to our dedicated page for Applied Genetic news (Ticker: AGTC), a resource for investors and traders seeking the latest updates and insights on Applied Genetic stock.
The AGTC (Applied Genetic Technologies Corporation) news archive on Stock Titan covers the company’s history as a clinical-stage biotechnology developer of adeno-associated virus (AAV)-based gene therapies for rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. News releases repeatedly describe AGTC’s focus on inherited retinal diseases, with its most advanced clinical programs in X-linked retinitis pigmentosa (XLRP) and achromatopsia due to CNGB3 variants (ACHM CNGB3).
Readers will find detailed coverage of the strategic transaction in which a portfolio company of Syncona Limited agreed to acquire AGTC through a tender offer and subsequent merger. Multiple releases from October through December 2022 outline the tender offer terms, the board’s unanimous recommendation, reminders to shareholders about tender deadlines, and the final confirmation that the acquisition closed and AGTC became an indirect, wholly owned subsidiary of Syncona Limited, with its common stock delisted from the Nasdaq Global Stock Market.
The archive also includes earlier corporate updates, such as announcements about AGTC’s participation in investor conferences and reiterations of its development strategy in AAV-based gene therapy, inherited retinal disease programs, and preclinical work in optogenetics, otology and CNS disorders. In addition, later news from Beacon Therapeutics references laru-zova (laruparetigene zovaparvovec), described in a presentation title as “AGTC-501,” providing continuity for those tracking the historical XLRP program originally developed at AGTC.
Investors, researchers and industry observers can use this news page to review AGTC’s public communications, understand the rationale and structure of the Syncona acquisition, and follow how AGTC’s legacy XLRP asset is referenced in subsequent clinical trial updates from Beacon Therapeutics.
Applied Genetic Technologies Corporation (AGTC) has reported positive results from its ongoing Phase 1/2 clinical program for X-linked retinitis pigmentosa (XLRP). The data shows durable improvements in visual sensitivity and visual acuity over a wide dose range, with a favorable safety profile. About 62% of patients in specific groups demonstrated significant responses. The company plans to initiate enrollment for its Phase 1/2 Skyline trial in Q4 2020 and the Phase 2/3 Vista trial in Q1 2021.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) will release 12-month data from its Phase 1/2 clinical trial for X-linked Retinitis Pigmentosa (XLRP) on November 11, 2020. The data will evaluate the durability of effect and safety across multiple patient groups. A conference call will be held at 8:00 AM ET on the same day to discuss the findings. AGTC is focused on developing gene therapies for rare diseases, with active clinical trials for XLRP and other conditions, aiming to address significant unmet clinical needs.
Applied Genetic Technologies Corporation (AGTC), a biotech company focused on gene therapies for rare diseases, announced participation in the Cantor Fitzgerald virtual panel on October 28, 2020, at 10:00 a.m. ET. CEO Sue Washer and VP Dave Knop will discuss key elements of gene therapy manufacturing and AGTC's proprietary processes. The panel will highlight company catalysts over the next year. AGTC is advancing clinical programs for inherited retinal diseases, leveraging its AAV technology for unmet clinical needs in various disorders.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has announced its participation in two upcoming virtual conferences in October 2020. The first is the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa, occurring from October 12-16, where CEO Sue Washer will present on-demand. The second event is the Dry AMD Therapeutic Development Summit on October 28-29, featuring CSO Mark Shearman in a panel discussion on dry AMD patient treatment. AGTC focuses on gene therapies for rare diseases, with clinical trials for inherited retinal diseases.
AGTC has joined the My Retina Tracker® Program as a scientific collaborator, enhancing its development of gene therapies for inherited retinal diseases. This partnership provides AGTC access to deidentified genetic data to identify candidates for clinical trials, focusing on X-linked retinitis pigmentosa (XLRP). AGTC's Phase 1/2 trial is expanding, with a Phase 2/3 trial planned for early 2021. The My Retina Tracker Program, in collaboration with Blueprint Genetics and the Foundation Fighting Blindness, offers no-cost genetic testing and counseling to affected individuals.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced its participation in three upcoming virtual conferences focused on biotechnology. The events include the Wells Fargo Virtual Healthcare Conference on September 10, 2020, where CEO Sue Washer will engage in a fireside chat, and the H.C. Wainwright Global Investment Virtual Conference from September 14-16, 2020, featuring investor meetings. Additionally, AGTC will participate in the Cantor Fitzgerald Global Healthcare Conference on September 16, 2020. Live audio webcasts of the presentations will be available online.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced the publication of preclinical data validating its gene therapy transgene (hRPGRco) for treating X-linked retinitis pigmentosa (XLRP). The study demonstrated that hRPGRco exhibited stronger expression and broader therapeutic index than alternative transgenes in a canine model, supporting its use in the ongoing Phase 1/2 clinical trial. AGTC plans to initiate a Phase 2/3 trial for the gene therapy in Q1 2021, with over 100 patients currently enrolled in clinical trials, showing favorable safety profiles.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced the formation of a Patient Advisory Council aimed at enhancing its patient-centric culture in clinical and pre-clinical programs. The council, led by Jill Dolgin, PharmD, includes advocates from the inherited retinal diseases community focusing on X-linked retinitis pigmentosa (XLRP). AGTC is also expanding its ongoing Phase 1/2 clinical trial and preparing for a Phase 2/3 trial expected to start in Q1 2021, following FDA feedback, to collect functional data on its gene therapy candidate.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced its inclusion in the Russell 3000® and 2000® Indexes, effective June 29, 2020. This addition reflects the company's advancements in gene therapies for rare diseases, particularly ongoing clinical programs like X-linked retinitis pigmentosa and achromatopsia. AGTC's CEO emphasized the boost in visibility and institutional interest resulting from the inclusion. Russell indexes manage approximately $9 trillion in assets, serving as benchmarks for investments, enhancing exposure for AGTC among investors.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has announced advancements in its manufacturing process for clinical trial materials, particularly for X-linked retinitis pigmentosa (XLRP). Improvements in their proprietary HSV-based process have resulted in AAV vector quality exceeding 90% full capsids and over 97% purity levels. Yields have increased more than tenfold compared to previous campaigns, allowing significant reductions in production costs. These advancements position AGTC to meet larger market demands and support future growth in gene therapy initiatives.
